Challenging and emerging pathogens in cystic fibrosis

Paediatric Respiratory Reviews

Volumn 11, Issue 4, 2010, Pages 246-254

  de Vrankrijker, A M M ^a   Wolfs, T F W ^a   van der EntC K , ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Burkholderia cepacia complex; Cystic fibrosis; Lung disease; Methicillin resistant Staphylococcus aureus; Non tuberculous mycobacteria; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Treatment

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZITHROMYCIN; CARBAPENEM; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; ETHAMBUTOL; FUSIDATE SODIUM; GENTAMICIN; IMIPENEM; MACROLIDE; PALIVIZUMAB; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL VIRULENCE; BRONCHIECTASIS; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; DRUG POTENTIATION; HUMAN; LUNG CAVITATION; LUNG DISEASE; LUNG NODULE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOBACTERIUM; NONHUMAN; NONTUBERCULOUS MYCOBACTERIUM; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY VIRUS; REVIEW; STENOTROPHOMONAS MALTOPHILIA; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS VIRULENCE;

BACTERIAL INFECTIONS; CHILD; CYSTIC FIBROSIS; HUMANS; PNEUMONIA, VIRAL; RESPIRATORY TRACT INFECTIONS;

EID: 78649444642     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2010.07.003     Document Type: Review

References (106)

1. Liou T.G., Adler F.R., FitzSimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153:345-352.
2. Smith J.J., Travis S.M., Greenberg E.P., Welsh M.J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996, 85:229-236.
3. Pilewski J.M., Frizzell R.A. Role of CFTR in airway disease. Physiol Rev 1999, 79:S215-S255.
4. Pier G.B. CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection. Curr Opin Microbiol 2002, 5:81-86.
5. Teichgraber V., Ulrich M., Endlich N., et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391.
6. Johnston S.L., Pattemore P.K., Sanderson G., et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995, 310:1225-1229.
7. Greenberg S.B., Allen M., Wilson J., Atmar R.L. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:167-173.
8. Rohde G., Wiethege A., Borg I., et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003, 58:37-42.
9. Hiatt P.W., Grace S.C., Kozinetz C.A., et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999, 103:619-626.
10. Ramsey B.W., Gore E.J., Smith A.L., Cooney M.K., Redding G.J., Foy H. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child 1989, 143:662-668.
11. Wang E.E., Prober C.G., Manson B., Corey M., Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984, 311:1653-1658.
12. Van Ewijk B.E., van der Zalm M.M., Wolfs T.F., et al. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics 2008, 122:1171-1176.
13. Abman S.H., Ogle J.W., Butler-Simon N., Rumack C.M., Accurso F.J. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988, 113:826-830.
14. Pribble C.G., Black P.G., Bosso J.A., Turner R.B. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. J Pediatr 1990, 117:200-204.
15. Smyth A.R., Smyth R.L., Tong C.Y., Hart C.A., Heaf D.P. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 1995, 73:117-120.
16. Zheng S., De B.P., Choudhary S., et al. Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity 2003, 18:619-630.
17. Colasurdo G.N., Fullmer J.J., Elidemir O., Atkins C., Khan A.M., Stark J.M. Respiratory syncytial virus infection in a murine model of cystic fibrosis. J Med Virol 2006, 78:651-658.
18. Johansen H.K., Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992, 47:109-111.
19. Petersen N.T., Hoiby N., Mordhorst C.H., Lind K., Flensborg E.W., Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand 1981, 70:623-628.
20. Ramphal R., Small P.M., Shands J.W., Fischlschweiger W., Small P.A. Adherence of Pseudomonas aeruginosa to tracheal cells injured by influenza infection or by endotracheal intubation. Infect Immun 1980, 27:614-619.
21. Van Ewijk B.E., Wolfs T.F., Aerts P.C., et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007, 61:398-403.
22. de Vrankrijker A.M., Wolfs T.F., Ciofu O., et al. Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol 2009, 81:2096-2103.
23. Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2009; CD001753.
24. Speer M.E., Fernandes C.J., Boron M., Groothuis J.R. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008, 27:559-561.
25. Robinson KA, Odelola OA, Saldanha I, McKoy N. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2010; 2:CD007743.
26. Denton M., Kerr K.G. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
27. Goss C.H., Otto K., Aitken M.L., Rubenfeld G.D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:356-361.
28. Sattler C.A., Mason E.O., Kaplan S.L. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis 2000, 31:1321-1330.
29. Talmaciu I., Varlotta L., Mortensen J., Schidlow D.V. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000, 30:10-15.
30. Demko C.A., Stern R.C., Doershuk C.F. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol 1998, 25:304-308.
31. Goss C.H., Mayer-Hamblett N., Aitken M.L., Rubenfeld G.D., Ramsey B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59:955-959.
32. Valdezate S., Vindel A., Maiz L., Baquero F., Escobar H., Canton R. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg Infect Dis 2001, 7:113-122.
33. Burns J.L., Emerson J., Stapp J.R., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27:158-163.
34. Graff G.R., Burns J.L. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002, 121:1754-1760.
35. Marchac V., Equi A., Le Bihan-Benjamin C., Hodson M., Bush A. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J 2004, 23:98-102.
36. Razvi S., Quittell L., Sewall A., Quinton H., Marshall B., Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009, 136:1554-1560.
37. Spicuzza L., Sciuto C., Vitaliti G., Di D.G., Leonardi S., La R.M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis 2009, 28:191-195.
38. Steinkamp G., Wiedemann B., Rietschel E., et al. Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 2005, 4:41-48.
39. Denton M., Todd N.J., Littlewood J.M. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996, 15:402-405.
40. Burns J.L., Van Dalfsen J.M., Shawar R.M., et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999, 179:1190-1196.
41. Elting L.S., Khardori N., Bodey G.P., Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990, 11:134-138.
42. Karpati F., Malmborg A.S., Alfredsson H., Hjelte L., Strandvik B. Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population. Infection 1994, 22:258-263.
43. Krueger T.S., Clark E.A., Nix D.E. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 2001, 41:71-78.
44. San Gabriel P., Zhou J., Tabibi S., Chen Y., Trauzzi M., Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 48:168-171.
45. Falkinham J.O. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002, 23:529-551.
46. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
47. Torrens J.K., Dawkins P., Conway S.P., Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998, 53:182-185.
48. Olivier K.N., Weber D.J., Wallace R.J., et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834.
49. Levy I., Grisaru-Soen G., Lerner-Geva L., et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008, 14:378-384.
50. Olivier K.N., Weber D.J., Lee J.H., et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003, 167:835-840.
51. Cullen A.R., Cannon C.L., Mark E.J., Colin A.A. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection?. Am J Respir Crit Care Med 2000, 161:641-645.
52. Kilby J.M., Gilligan P.H., Yankaskas J.R., Highsmith W.E., Edwards L.J., Knowles M.R. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992, 102:70-75.
53. Esther C.R., Esserman D.A., Gilligan P., Kerr A., Noone P.G. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010, 9:117-123.
54. Wallace R.J., Brown B.A., Griffith D.E., Girard W.M., Murphy D.T. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996, 153:1766-1772.
55. Cremades R., Santos A., Rodriguez J.C., Garcia-Pachon E., Ruiz M., Royo G. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. J Infect Chemother 2009, 15:46-48.
56. Li Z., Kosorok M.R., Farrell P.M., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293:581-588.
57. Saiman L. Microbiology of early CF lung disease. Paediatr Respir Rev 2004, 5(Suppl A):S367-S369.
58. Pressler T., Frederiksen B., Skov M., Garred P., Koch C., Hoiby N. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection-a case control study. J Cyst Fibros 2006, 5:9-15.
59. Sly P.D., Brennan S., Gangell C., et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009, 180:146-152.
60. Romling U., Fiedler B., Bosshammer J., et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis 1994, 170:1616-1621.
61. Jensen E.T., Giwercman B., Ojeniyi B., et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J Hosp Infect 1997, 36:117-122.
62. Speert D.P., Campbell M.E., Henry D.A., et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002, 166:988-993.
63. Grothues D., Koopmann U., von der H.H., Tummler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988, 26:1973-1977.
64. Ojeniyi B., Frederiksen B., Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 2000, 29:177-181.
65. Cheng K., Smyth R.L., Govan J.R., et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996, 348:639-642.
66. Jones A.M., Govan J.R.W., Doherty C.J., et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001, 358:557-558.
67. Armstrong D.S., Nixon G.M., Carzino R., et al. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002, 166:983-987.
68. Fluge G., Ojeniyi B., Hoiby N., et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin Microbiol Infect 2001, 7:238-243.
69. Scott F.W., Pitt T.L. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 2004, 53:609-615.
70. Jelsbak L., Johansen H.K., Frost A.L., et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect Immun 2007, 75:2214-2224.
71. van Mansfeld R., Willems R., Brimicombe R., et al. Pseudomonas aeruginosa genotype prevalence in Dutch cystic fibrosis patients and age dependency of colonization by various P. aeruginosa sequence types. J Clin Microbiol 2009, 47:4096-4101.
72. Tingpej P., Smith L., Rose B., et al. Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis. J Clin Microbiol 2007, 45:1697-1704.
73. Salunkhe P., Smart C.H., Morgan J.A., et al. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol 2005, 187:4908-4920.
74. Jones A.M., Dodd M.E., Doherty C.J., Govan J.R., Webb A.K. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002, 57:924-925.
75. Al-Aloul M., Crawley J., Winstanley C., Hart C.A., Ledson M.J., Walshaw M.J. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 2004, 59:334-336.
76. O'Carroll M.R., Syrmis M.W., Wainwright C.E., et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur Respir J 2004, 24:101-106.
77. Griffiths A.L., Jamsen K., Carlin J.B., et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 2005, 171:1020-1025.
78. Jones A.M., Dodd M.E., Morris J., Doherty C., Govan J.R., Webb A.K. Clinical outcome for cystic fibrosis patients infected with transmissible P. aeruginosa: an 8 year prospective study. Chest 2010.
79. Pedersen S.S., Koch C., Hoiby N., Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986, 17:505-516.
80. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
81. Gibson R.L., Emerson J., McNamara S., et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849.
82. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23:330-335.
83. Dasenbrook E.C., Merlo C.A., ener-West M., Lechtzin N., Boyle M.P. Persistent Methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:814-821.
84. Cystic Fibrosis Foundation. Patient Registry 2008 Annual Report. 2010. Bethesda, Maryland.
85. Millar F.A., Simmonds N.J., Hodson M.E. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009, 8:386-391.
86. Wassenberg M.W., Kluytmans J.A., Box A.T., et al. Rapid screening of Methicillin-resistant Staphylococcus aureus (MRSA) using PCR and chromogenic agar: a prospective study to evaluate costs and effects. Clin Microbiol Infect 2010.
87. Ren C.L., Morgan W.J., Konstan M.W., et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007, 42:513-518.
88. Boxerbaum B., Jacobs M.R., Cechner R.L. Prevalence and significance of Methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmonol 1988, 4:159-163.
89. Miall L.S., McGinley N.T., Brownlee K.G., Conway S.P. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001, 84:160-162.
90. Thomas S.R., Gyi K.M., Gaya H., Hodson M.E. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect 1998, 40:203-209.
91. Solis A., Brown D., Hughes J., Van Saene H.K., Heaf D.P. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. Pediatr Pulmonol 2003, 36:189-195.
92. Macfarlane M., Leavy A., Mccaughan J., Fair R., Reid A.J. Successful decolonization of Methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 2007, 65:231-236.
93. Garske L.A., Kidd T.J., Gan R., et al. Rifampicin and sodium fusidate reduces the frequency of Methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 2004, 56:208-214.
94. UK Cystic Fibrosis Trust Infection Control working Group. Methicillin resistant Staphylococcus aureus (MRSA). UK CF Trust; 2008.
95. Yabuuchi E., Kosako Y., Oyaizu H., et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992, 36:1251-1275.
96. Vandamme P., Henry D., Coenye T., et al. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol 2002, 33:143-149.
97. Kiska D.L., Kerr A., Jones M.C., et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 1996, 34:886-891.
98. Henry D.A., Campbell M.E., Lipuma J.J., Speert D.P. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997, 35:614-619.
99. Coenye T., Vandamme P., Govan J.R., Lipuma J.J. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001, 39:3427-3436.
100. Whiteford M.L., Wilkinson J.D., McColl J.H., et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995, 50:1194-1198.
101. Govan J.R., Brown P.H., Maddison J., et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993, 342:15-19.
102. Lipuma J.J. Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med 1998, 4:337-341.
103. Isles A., MacLusky I., Corey M., et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984, 104:206-210.
104. Lewin L.O., Byard P.J., Davis P.B. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990, 43:125-131.
105. Lipuma J.J. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med 2003, 24:681-692.
106. Aaron S.D., Ferris W., Henry D.A., Speert D.P., Macdonald N.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000, 161:1206-1212.